In a phase I pilot study (NCT05168423) evaluating CAR-T-EGFR-IL13Ra2 cells, pseudo-tumor progression was observed a month post-infusion; however, overall tumor size decreased by two months post-infusion [49]. Here, EGFR is linked to neoplasm.